CN203303031U - Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum - Google Patents
Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum Download PDFInfo
- Publication number
- CN203303031U CN203303031U CN2013202551847U CN201320255184U CN203303031U CN 203303031 U CN203303031 U CN 203303031U CN 2013202551847 U CN2013202551847 U CN 2013202551847U CN 201320255184 U CN201320255184 U CN 201320255184U CN 203303031 U CN203303031 U CN 203303031U
- Authority
- CN
- China
- Prior art keywords
- optical fiber
- light
- light source
- luminous
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
Images
Landscapes
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The utility model relates to a diabetes non-invasive detecting device based on a glycation end product fluorescence spectrum. The diabetes non-invasive detecting device based on the glycation end product fluorescence spectrum comprises a light source part, a light control part, a light source fiber, a probe part, a probing fiber, a spectrum part and a data processing part, wherein the light source part, the light control part, the light source fiber and the probe part are sequentially connected and the probing fiber, the spectrum part and the data processing part are sequentially connected with the probe part. The diabetes non-invasive detecting device based on the glycation end product fluorescence spectrum overcomes the defect that the blood of a patient needs collecting according to an existing diabetes detecting device. According to the fluorescence effect of the glycation end product in the human body skin tissue, the non-invasive rapid detection of the diabetes is achieved.
Description
Technical field
This utility model relates to and a kind of human body skin is carried out to optical detection apparatus, a kind of noninvasive detection device of diabetes based on the Advanced glycation end products fluorescence spectrum particularly, help the medical worker to detect the experimenter and whether suffer from diabetes, and the assessment experimenter suffers from the risk of diabetes and complication thereof.
Background technology
Relate to the large-scale diabetes study demonstration of totally 270 ten thousand populations (>=25 years old) of 199 countries, whole world diabetes population by 1980 1.53 hundred million increase to 2008 3.47 hundred million, wherein, the ill ratio of men age markization by 1980 8.3% increase to 2008 9.8%, the women increases to 9.2% by 7.5%.In addition, year May in June, 2007 to 2008, the Diabetes Epidemiological Investigation of carrying out in Chinese population (age >=20 year old) shows, the age adjusted prevalence of diabetes and prediabetes is respectively the 9.7%(man, the women is respectively 10.6% and 8.8%) and 15.5%(man, women be respectively 16.1% and 14.9%).
In the diabetics body, long-term hyperglycemia can cause than macrolesion its health, and often with multiple complications such as nephropathy change, retinopathy, neuropathy, vascular change at lower extremities, diabetic foots, life and quality of life to the patient threaten greatly, have brought heavy financial burden for patient individual and family.A kind of (even more) diabetic complications have occurred while having the diabetics of significant proportion to be made a definite diagnosis.The health care expense in the whole world 11.6% in 2010 spends in prevents and treats on diabetes, and World Health Organization (WHO) estimates that 2005 to 2015 China is because the economic loss that diabetes and related cardiovascular disease cause reaches 5,577 hundred million dollars.Diabetes have become Chinese important public hygiene problem.
At present, the clinical diagnosis Main Basis venous plasma blood glucose of diabetes.China adopts WHO(1999) carbohydrate metabolism state classification standard and diagnostic criteria.The carbohydrate metabolism state can be divided into four classes, is respectively euglycemia, impaired fasting glucose (IFG), impaired glucose tolerance and diabetes.The diabetes diagnosis standard can be divided three classes: (1) diabetic symptom (the acute metablize confusion performances such as the polydipsia that hyperglycemia causes, polyphagia, polyuria, weight loss, skin pruritus, blurred vision), and random blood sugar >=11.1mmol/L; (2) fasting glucose (FPG) >=7.0mmol/L; (3) 2h blood glucose >=11.1mmol/L after glucose load.Wherein, on an empty stomach state refers at least the 8h heat of not taking food, and random blood sugar refers to not consider meal time last time, the blood glucose of random time in one day.After FPG or 75g glucose OGTT, the 2hPG value can be separately for Epidemiological study or Mass screening.
In conventional diabetes detection method, the sensitivity of fasting glucose method (FPG) is low, and the coefficient of variation is larger, needs empty stomach more than 8 hours, and is subject to the impact of patient compliance, centrifugal blood time, laboratory error and medicine; There are the deficiencies such as the influence factor is many, poor repeatability in oral glucose tolerance experiment (OGTT).People more and more are inclined to using HbA1c as the examination High-risk Group of Diabetes and detect a kind of method of diabetes in recent years.HbA1c is simple and easy to do than the OGTT test, and result is stable, and variability is little, and is not subjected to the impact of eating time and short-term lifestyle change, and patient compliance is good.In addition, above-mentioned diabetes detection method all needs blood sample collection, when to the experimenter, bringing pain, has also increased infected risk.China is populous, by blood sugar test, carrys out examination prediabetes patient and finds that systematically other high-risk group do not have feasibility in total man group.Many diabeticss are just to go to carry out the blood sample test when sensation health significant discomfort, have delayed to a certain extent diabetes and have made a definite diagnosis the time, very unfavorable to treatment.The diabetics of China 60.7% is not diagnosed and can't effectively be treated early.Along with the raising of living standards of the people, the enhancing of health perception, the detection of diabetes and pre-Radix Stephaniae Tetrandrae become the important topic of social concerns, in the urgent need to a kind of noinvasive, diabetes detection efficiently, the methods of risk assessment of diabetes and complication thereof, these prevention and control to diabetes are significant.
The diabetics body contains excessive Advanced glycation end products.Advanced glycation end products does not slowly increase in suffering from the diabetic subjects tissue, but, in the diabetics body, has accelerated the generation of Advanced glycation end products owing in circulation, continuing high sugar level, and it is accumulated in a large number.The excessive Advanced glycation end products produced not only can with protein cross, affect protein performance, also can by with special receptors bind, react to change cell function, thereby cause the pathological change of body.Thereby the genesis of the diabetic complications such as Advanced glycation end products and diabetic nephropathy, retinopathy, neuropathy, atherosclerosis is closely related.
Since the last century the eighties, various countries scientist and technical staff detect the Advanced glycation end products in human serum or skin with kinds of schemes, as radioreceptor assay, radioimmunology, enzyme linked immunosorbent assay, high performance liquid chromatography etc., but the operating process of these methods is loaded down with trivial details, and all need isolated experiment, hindered application and the popularization of Advanced glycation end products index in diabetes detection and complication prediction.Advanced glycation end products has the characteristic of stimulated emission fluorescence under ultraviolet radiation, therefore can, by measuring the Advanced glycation end products fluorescence spectrum, reflect its concentration and distribution in body.With traditional method, compare, detect and do not need the sampling chemical examination based on the Advanced glycation end products of fluorescent spectrometry, also without reagent, possess in real time, the advantages such as noinvasive, safety.
Based on skin Advanced glycation end products fluorescence, realize the detection of diabetes, prediabetes or diabetic complication, the experimenter without on an empty stomach, blood sampling, and obtain in real time measurement result.
In implementing process of the present utility model, utility model people finds that there are following shortcoming in existing skin Advanced glycation end products fluoroscopic examination and application: the excitation light irradiation tissue that usually uses shorter wavelength in (1) prior art, then collection organization's emergent light, for spectrum analysis.In this process, usually with the combination of a plurality of light sources and/or a plurality of optical filters, realize the separation detection of two or more wavelength.No matter with the mechanical displacement platform, select light source still with optical filter wheel, to select optical filter, all, likely because the factors such as mechanical vibration, coupling loss cause optical condition in test process to change, bring error to measurement result; (2) fluorescence recorded at skin surface, be that the fluorescent material in the skin histology aspect that exciting light is penetrated into sends, and escape into skin surface.Human body skin is a kind of turbid medium with multiple structure.Different people, same people's different test positions, the different depth of same test position, all have larger difference to absorption and the scattering of light.The double-absorption scattering process of skin to exciting light and fluorescence, can hide the real difference of different experimenter's skin Advanced glycation end products concentration.Though prior art has been carried out certain correction to the skin ABSORPTION AND SCATTERING, in correcting algorithm, do not consider the relation of ABSORPTION AND SCATTERING and optical wavelength, calibration result is poor; (3) geometry that adopts of the outgoing of exciting light and radiative collection has a great impact intensity and the spectral shape that records skin Advanced glycation end products fluorescence.The geometry of outgoing structure has determined the distribution characteristics of exciting light, thereby affects the distributed in three dimensions of emitting fluorescence.Prior art does not have targetedly, according to multilamellar characteristic and the distribution character of Advanced glycation end products in human skin tissue of human skin tissue, in the design of probe component, to choose suitable excitation fiber and detection optical fiber distribution distance; (4) factors such as measurand skin surface physical state such as color, temperature, humidity, pressure, can have a certain impact to fluorescence measurement, and prior art is not revised this; (5) there is some difference in the crowd of different physiological features for Advanced glycation end products, need to revise for the physiological feature of measurand.Prior art is revised less than factors such as the age for measurand, sex, height, body weight.
The utility model content
This utility model technology is dealt with problems: overcome the deficiency that existing diabetes detecting device need to gather blood samples of patients, a kind of noninvasive detection device of diabetes based on the Advanced glycation end products fluorescence spectrum is provided, according to the fluorescent effect of Advanced glycation end products in human skin tissue, realize without wound fast detecting diabetes.
This utility model technical solution: a kind of noninvasive detection device of diabetes based on the Advanced glycation end products fluorescence spectrum, to determine whether the experimenter suffers from diabetes and predict the ill risk of diabetic complication, this checkout gear comprises successively light source part, light-operated parts, luminous source optical fiber and the probe component connected, and the detection optical fiber, spectral components and the data processor that are connected successively with probe component.
1. the light source part in this checkout gear is luminous organ and the luminous power of electrical connection, and luminous power offers the stable power supply of luminous organ, and the luminous wave band of luminous organ is 300～400nm and 420～780nm; Luminous organ can be one or more the combination in light emitting diode, electric filament lamp, Halogen light, neon lamp.Light source part is with the temperature sensor be connected with luminous organ, and the outfan of this temperature sensor is connected with the input of light-source temperature controller; The light-source temperature controller is the temperature of measurement light source in real time, and makes light source keep temperature constant, makes the light that light source sends keep stable.
2. light-operated parts comprise focusing bonder and the light splitting piece be positioned on the light source part light path, the transmission end of light splitting piece is connected with luminous source optical fiber, be equipped with the optical-electrical converter that its outfan is electrically connected to light source controller on reflected light path, and the outfan of described light source controller is electrically connected to the input of light source part.
3. luminous source optical fiber is the first luminous source optical fiber and the secondary light source optical fiber be connected in parallel, and is respectively used to the light source that transmission wavelength is 300～400nm and 420～780nm; All optical fiber all has lower optical transmission loss in long wave ultraviolet and visible waveband.
4. the probe component detection optical fiber end face having placed at grade the first luminous source optical fiber end face be communicated with the first luminous source optical fiber, the secondary light source fiber end face be communicated with secondary light source optical fiber, be communicated with detection optical fiber; In addition, color sensor, temperature sensor, humidity sensor and pressure transducer also have been installed; Many luminous source optical fibers on probe component are all identical with the distance (while arriving) between detection optical fiber, this distance be 0.1mm to the fixed value between 3mm, make the light of collecting more from the Advanced glycation end products in the human skin tissue skin corium.
5. on the detection optical fiber between detection optical fiber end face and spectral components, be equipped with filter part, filter part is a kind of optical filter, at the transmitance of wavelength 420～780nm wave band >=80%, have mild rising edge and high permeability≤10%, transmitance≤1% at wavelength during lower than 300nm at wavelength 300～400nm wave band.The optical filter of this non-cut-off application makes when avoiding exciting light to cause that spectral components is saturated overflowing, and also can receive the part exciting light after decay.Not exclusively getting rid of exciting light can make algorithm to human body skin Advanced glycation end products fluorescence, revise in conjunction with the organizational information that the exciting light be reflected back comprises.Make can to avoid in this way optical filter wheel in common fluoroscopic examination application or the action of other mechanical parts, with this interference of avoiding mechanical action to bring.Symmetrical the first luminous source optical fiber end face of the periphery of detection optical fiber end face and secondary light source fiber end face, the mutual back gauge of the first luminous source optical fiber end face and secondary light source fiber end face and detection optical fiber end face is 0.1～3mm;
6. the spectral components of this checkout gear is fiber spectrometer, and the light intensity degree of each wavelength of input light is measured and quantized to spectral components, and measurement result outputs in data processor; Fiber spectrometer has optical signal input and detection signal outfan, and the optical signal input of fiber spectrometer and the back segment of detection optical fiber are coupled by optical filter; When fiber spectrometer is work, can measure and quantize to input the device of the light intensity degree of each wavelength of light, its measurement result can output to data transmission and processing and memory element.
7. data processor is microcomputer, can receive above-mentioned measurement result by its detection signal input during use; Data processor can calculate respectively according to measured spectrum information and the radiative information of exciting light in the received light line; And can calculate human skin tissue primary fluorescence intensity and distribution and calculate the device of Advanced glycation end products content according to above-mentioned exciting light and radiative information; Can also to result of calculation, screen or revise according to information such as the color on the information such as age of the measurand of user input, sex, height, body weight and human body skin surface, temperature, humidity, pressure.According to age, the sex information of measurand, determine judgment threshold, obtain final diabetes testing result.
8. color sensor is electrically connected to data processor through the first preamplifier and the first analog-digital converter.Temperature sensor is electrically connected to data processor through the second preamplifier and the second analog-digital converter.Humidity sensor is electrically connected to data processor through the 3rd preamplifier and the 3rd analog-digital converter.Pressure transducer is electrically connected to data processor through the 4th preamplifier and the 4th analog-digital converter.
9. probe component is with the aligner of outstanding detection optical fiber end face 1～5mm, and aligner is 95～100% reflector plate for the reflectance that is 300～780nm to wavelength.
This utility model compared with prior art has the following advantages:
(1) Advanced glycation end products is long-term accumulation in human body, thereby stable based on the testing result of Advanced glycation end products, is not subjected to the impact of season, period; This utility model checkout gear utilizes SF reflection human body whether to suffer from diabetes and assesses the probability of complications, detect consuming time short, and, without human body being carried out to blood test or skin biopsy sampling, avoided the painful and infected risk of bringing to patient.
(2) checkout gear of the present utility model adopts the combination of various light sources, measure in real time skin and at Advanced glycation end products, excite the reflectance of wave band and emission band, to proofread and correct the ABSORPTION AND SCATTERING effect of skin, can reduce the impact of experimenter's skin difference on measurement result.
(3) in checkout gear of the present utility model, adopt specific probe component structure, make the fluorescence of collecting more from the Advanced glycation end products in the human skin tissue skin corium, improve the accuracy of measuring.
(4) in this utility model, adopt the long wavelength with inclination rising edge to pass through the type optical filter, when realizing fluorescence and wide range reflected light measurement, reduced the complexity of instrument light channel structure, guaranteed the stable of optical condition.
(5) checkout gear of the present utility model, according to the physical state of personal information, physiological feature and the skin surface of measurand, is revised measurement result, has improved the accuracy that diabetes detect.
The accompanying drawing explanation
Fig. 1 is the composition frame chart of this utility model checkout gear;
Fig. 2 a, Fig. 2 b, Fig. 2 c, Fig. 2 d are respectively fiber distribution example in the probe component in this utility model; Wherein zero means luminous source optical fiber; ● mean detection optical fiber;
Fig. 3 is luminous source optical fiber and the detection optical fiber spacing impact on reflected light and fluoroscopic examination in this utility model;
Fig. 4 is that contact pressure is on catoptrical impact;
Saturated the overflowing of Fig. 5 (a) exciting light caused sideband effect; Fig. 5 (b) adopts the long wavelength with inclination rising edge by the type optical filter, can decay and don't as for ending exciting light fully;
Fig. 6 has the long wavelength of inclination rising edge by the spectral response curve of type optical filter;
Fig. 7 a is the cutaway view of the aligner that adopts in this utility model,
Fig. 7 b is the axonometric chart of the aligner that adopts in this utility model;
Fig. 8 a is the relation between male's matched group age and measured value in this utility model test;
Fig. 8 b is the relation between women's matched group age and measured value in this utility model test;
Fig. 9 is the sensor location figure on the fibre-optical probe end face in this utility model;
Screening when Figure 10 is the measurement of this utility model checkout gear and the decision flowchart of measurement result.
The specific embodiment
This utility model is mainly that human skin tissue is carried out to optical detection, according to human skin tissue, the response of light source is carried out to respective handling and obtain distinguishable result, help the medical worker to determine the probability whether tested personnel suffer from diabetes and predict its trouble complication with this.
As shown in Fig. 1,9,10, this utility model checkout gear comprises: the light source part 1, light-operated parts 2, luminous source optical fiber 3 and the probe component 4 that connect successively, and the detection optical fiber 5, spectral components 7 and the data processor 8 that are connected successively with probe component 4.
Light source part 1 comprises luminous organ 11 and luminous power 12; Light-operated parts 2 comprise focusing bonder 21 and light splitting piece 22; The printing opacity end of light splitting piece 22 is connected with luminous source optical fiber 3, and reflection end is connected with the input of optical-electrical converter 23; The outfan of optical-electrical converter 23 is electrically connected to the input of light source controller 24; The outfan of light source controller 24 is electrically connected to the input of light source part 1; First luminous source optical fiber 31 and the secondary light source optical fiber 32 of luminous source optical fiber 3 for being connected in parallel; Probe component 4 comprises the first luminous source optical fiber end face 41 be communicated with the first luminous source optical fiber 31, the secondary light source fiber end face 42 be communicated with secondary light source optical fiber 32, the detection optical fiber end face 43 be communicated with detection optical fiber 5, color sensor 44, temperature sensor 45, humidity sensor 46 and pressure transducer 47; Color sensor 44 is electrically connected to data processor 8 through the first preamplifier 441 and the first analog-digital converter 442; Temperature sensor 45 is electrically connected to data processor 8 through the second preamplifier 451 and the second analog-digital converter 452; Humidity sensor 46 is electrically connected to data processor 8 through the 3rd preamplifier 461 and the 3rd analog-digital converter 462; Pressure transducer 47 is electrically connected to data processor 8 through the 4th preamplifier 471 and the 4th analog-digital converter 472; On detection optical fiber 5 between detection optical fiber end face 43 and spectral components 7, be equipped with filter part 6; The optical signal input of spectral components 7 and the back segment of detection optical fiber are coupled by optical filter 6.
When this utility model device is used, by light source part 1, sent the light of 300～400nm and 420～780nm.300～400nm light puts together light through focusing on bonder 21, through light splitting piece 22, light is divided into to two bundles again, wherein a branch ofly by the first luminous source optical fiber 31, transfer to the first luminous source optical fiber end face 41, for exciting the skin histology Advanced glycation end products to produce fluorescence and characterize skin, exciting the reflectance of wave band, another bundle leads to optical-electrical converter 23 and is converted to the signal of telecommunication.420～780nm light puts together light through focusing on bonder 21, through light splitting piece 22, light is divided into to two bundles again, wherein a branch ofly by secondary light source optical fiber 32, transfer to secondary light source fiber end face 42, for measuring the reflectance spectrum of skin at the fluorescence wave band, another bundle leads to optical-electrical converter 23 and is converted to the signal of telecommunication.The signal of telecommunication that optical-electrical converter 23 obtains is for characterizing the intensity of current light source, and this signal of telecommunication access light source controller 24, can, according to the unsteady correction output light intensity of light source power, keep exporting the stable of light with this in light source controller 24.Luminous organ 11 in light source part 1 and luminous power 12 are all controlled by light source controller 24, can open or close as required certain luminous organ 11 and luminous power 12, by the mode that circuit is controlled, luminous organ 11 and luminous power 12 are combined, avoided the vibration of using mechanical adjustment mode to bring, the problem such as unstable.
Luminous source optical fiber 3 comprises the first luminous source optical fiber 31 and the secondary light source optical fiber 32 be connected in parallel, and can be optical fiber or fibre bundle, can be liquid-core optical fibre or silica fibre, can be the light pipe of any transparent material.As shown in Figure 2 a-2d, when luminous source optical fiber 3 had many, distribution was centrosymmetric centered by detection optical fiber 5.In the present embodiment, luminous source optical fiber 3 numerical apertures are 0.22, and core diameter is 200 μ m.Every luminous source optical fiber 3 to detection optical fiber 5 apart from while arriving, being identical, and be a fixed value.The first luminous source optical fiber end face 41, secondary light source fiber end face 42 and detection optical fiber end face 43 have formed probe component 4 jointly, the general centering part of detection optical fiber end face 43 on probe component 4.In the present embodiment, detection optical fiber 5 is silica fibre, and its numerical aperture is 0.22, and core diameter is 800 μ m.
Irradiate light in luminous source optical fiber 3 is behind the human skin tissue surface, and a part of light is by the skin surface diffuse-reflectance, and a part of light is injected in skin histology.A light part of injecting in skin histology is absorbed by tissue and causes the Advanced glycation end products in skin histology to produce fluorescence, and scattering occurs a part.The optical propagation direction of scattering will change, and a part of light will appear from skin surface again after continuous direction changes.Propagation due to light in skin histology always trends towards forward direction, i.e. it is all smaller that the direction that each scattering occurs changes angle value.As shown in Figure 3, the light that appears close to will be mainly the light that arrives or result from the skin shallow-layer from luminous source optical fiber 3; The light that appears from luminous source optical fiber 3 away from will be mainly the light that arrives or result from deep skin.Due to Advanced glycation end products, in skin, mainly be distributed in the skin corium of certain depth, therefore should to meet the light intensity of the Advanced glycation end products fluorescence that makes to come from the light of collecting in detection optical fiber skin corium the strongest for the distance between luminous source optical fiber 3 and detection optical fiber 5, and in the present embodiment, this distance is 500 μ m.
In addition, after skin histology, also scattering and absorption can occur at the fluorescence of the Advanced glycation end products produced in skin histology, its spectrum will change.If correct, obtain the Advanced glycation end products fluorescence spectrum in skin histology, must the propagation in skin histology revise according to light.Therefore, do not use the optical filter of a sharp cut-off between detection optical fiber 5 and spectral components 7, but the filter part 6 that has used a long wavelength with inclination rising edge to pass through.This filter part 6 can be by the Advanced glycation end products fluorescence of most of 420～780nm wave-length coverage, simultaneously also can pass through the source light of fraction 300～400nm wave-length coverage, therefore the light of collecting in detection optical fiber 5 not only comprises fluorescence, also comprises a part of exciting light.And, adopt filter part 6 that long wavelength with inclination rising edge passes through most of exciting light of can decaying, avoided exciting light to cause excessively by force that spectral components 7 is saturated overflows.The exciting light be attenuated will be for the correction to fluorescence spectrum, to obtain the true fluorescence spectrum of Advanced glycation end products in human skin tissue.The non-application of cut-off fully of this filter part 6 has avoided in the prior art usually with the combination of a plurality of light sources and/or a plurality of optical filters, realizing the separation detection of two or more wavelength.No matter with mechanical displacement platform or similar means, select light source still with optical filter wheel or similar means, to select optical filter, all can cause optical condition in experiment to change because of factors such as mechanical vibration, make measurement result inaccurate.As shown in Figure 5,1 is exciting light, and 2 is fluorescence, and 3 for recording spectrum, and 4 is filter part, and 5 are the spectrum that records after filter part 6.Fig. 6 is the spectral response curve of this filter part 6.
Through detection optical fiber 5, collect and light by filter part 6 is input in spectral components 7, in this light intensity by each wavelength, be converted into the signal of telecommunication of corresponding each wavelength, this signal of telecommunication is input to data processor 8.
Adopt the diffuse reflection spectrum that covers exciting light and emission spectra scope to proofread and correct fluorescence Spectra, in correcting algorithm, both adopted the reflectance that excites wave band, comprised again the reflectance of fluorescence wave band, the fluorescence spectrum F after correction
Corr(λ
m) be calculated as:
Wherein, F
Meas(λ
m),
And R (λ
m) be respectively the reflectance of the SF obtained, the reflectance that excites wave band, fluorescence wave band.λ
xWith λ
mRespectively corresponding excitation wavelength and wavelength of fluorescence.In addition, the k related in formula
xAnd k
m, its value, between 0 to 1, and is subject to surveying the impact of light path geometry.
This utility model suffers from the judgement of diabetes based on the statistical analysis to great amount of samples (comprising ND and diabetics) measurement result to the measurand possibility.Experiment by statistics, consider simultaneously a certain experimenter repeatedly measurement result have higher concordance, and agematched ND's measurement result has concordance preferably, finally chooses k
x, k
mBe respectively 0.5,0.35.
In addition, due to the inherent character of statistical analysis technique, measurand must meet certain statistical distribution requirements.In this utility model, the data such as skin color, temperature, humidity, pressure, height, body weight of all measurands have been recorded, and with normal distribution, carry out the distribution of these data of match, two standard deviations are respectively departed from each mean parameter left and right that is based on measurand of choosing of following numerical range.
According to the skin surface color, measurement result is screened:
This checkout gear utilizes human skin tissue to measure the response of light, so the color of skin will produce great impact to measurement result, and the result that must use this sensor to record is screened measurement result.
The color sensor 44 adopted is TCS3200.The data that gather show, positive and negative two the standard deviation scopes of the skin color gray value meansigma methods of measurand are 185～245.Therefore, limit and only the measurand be within this scope is provided to testing result, while exceeding this scope, can't guarantee that data are effective.
According to skin surface temperature, measurement result is screened:
Temperature numerical has partly reflected the state of organizing in skin, and under condition of different temperatures, human skin tissue will present different states.For example, there is the trend of contraction on the human body skin surface when temperature is low; When temperature was lower, the human body skin surface will produce stress, will have a strong impact on the measurement to optical signal in skin histology, therefore need to measurement result, screen according to temperature value.
The temperature sensor 45 of adopting is DS18B20.The data that gather show, positive and negative two the standard deviation scopes of the skin surface temperature value meansigma methods of measurand are 26 ℃～35 ℃ (during test, keeping ambient temperature is 27 ℃).Therefore, limit and only the measurand be within this scope is provided to testing result, while exceeding this scope, can't guarantee that data are effective.
According to skin surface humidity, measurement result is screened:
The variation of human body skin surface moisture has reflected the perspire state of human body, and perspiration will obviously change the optical transmission characteristics on human skin tissue surface, therefore must to measurement result, screen according to humidity value.
The humidity sensor 46 adopted is SHT11.The data that gather show, positive and negative two the standard deviation scopes of the skin surface humidity value meansigma methods of measurand are 42%～60%.Therefore, limit and only the measurand be within this scope is provided to testing result, while exceeding this scope, can't guarantee that data are effective.
According to skin surface pressure, measurement result is screened:
Contact pressure reflected probe component 4 and human skin tissue surface label and degree.Pressure can cause the variation of microstructure in skin histology, thereby change its optical parametric, measurement result is changed.As table 1 and experiment shown in Figure 4, show, for same measurand same position, if probe component 4 is divided into " contacting (A; approximately 2.1 Ns) ", " than close contact (B; approximately 3.6 Ns) ", " close contact (C; approximately 5.2 Ns) " with the tightness degree of contact skin, along with the increase of contact pressure, directly intensity of reflected light can weaken.And, the tightness difference of contact, the fluctuation range of measured value is different, A fluctuation range maximum, B and C fluctuation range are all smaller and difference is little.
The pressure transducer 47 used in this checkout gear is MSP20N0040D, points out and makes measurand adjust attitude to take and guarantee that probe pressure is 3.6 ± 0.5 Ns, can't guarantee while exceeding this scope that data are effective by software interface.
Table 1, the impact of exposure level on measurement result
| Exposure level | A | B | C |
| Measurement result standard deviation meansigma methods | 0.0310 | 0.0148 | 0.0178 |
After in spectral components 7, measuring spectral signal, send into data processor 8, calculate PRELIMINARY RESULTS, the information such as the skin color recorded through color sensor 44, temperature sensor 45, humidity sensor 46 and pressure transducer 47 again, temperature, humidity, pressure are screened, then according to information such as measured's height of inputting in data processor 8, body weight, revise, then determine whether according to measured's age, sex and measured value the risk of suffering from diabetes and occurrence of diabetes complication.
According to height and the body weight of measurand, measurement result is screened:
As shown in Fig. 8 a and Fig. 8 b, the data of collection show, two standard deviation scopes of the height of measurand and the meansigma methods of body weight are: women, height are between 1.4 meters～1.75 meters, and body weight is between 35 kilograms～80 kilograms; The male, height is between 1.55 meters～1.9 meters, and body weight is between 45 kilograms～90 kilograms.Therefore, limit and only the measurand be within this scope is provided to testing result, while exceeding this scope, can't guarantee that data are effective.
According to age and the sex of measurand, adjust threshold value:
The data that control group (ND's group) gathers are carried out to match, between the age of measurand (x) and data measured (y), have following relation:
The male, y=0.392x+44.26
The women, y=0.440x+46.73
According to Statistical Distribution, the diabetes detection threshold limit (Y) that all ages and classes (x) is corresponding is set in the method and is respectively:
The male, Y=0.498x+56.29
The women, Y=0.603x+59.41
Also namely, by after the above-mentioned formula of age substitution of measurand, if measured value is greater than the result of calculation of this formula, show that namely this measurand suffers from diabetes.
As shown in Fig. 7 a and Fig. 7 b, this utility model device also comprises an aligner 48, and aligner 48 is standard Teflon diffuse reflector, has more smooth reflection characteristic at the 300-780nm wave band, and reflectance is greater than 99%.During use, this aligner 48 is positioned on probe component 4, then in data processor 8, open calibration function, data processor 8 will the automatic Calibration instrument spectral response record in addition, if record the undesired data processor 8 of spectral response, need to again demarcate.
This utility model does not elaborate part and belongs to techniques well known.
The above; it is only this utility model part specific embodiment; but protection domain of the present utility model is not limited to this; any those skilled in the art are in the technical scope that this utility model discloses; the variation that can expect easily or replacement, within all should being encompassed in protection domain of the present utility model.
Claims (7)
1. noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum, it is characterized in that comprising: the light source part (1), light-operated parts (2), luminous source optical fiber (3) and the probe component (4) that connect successively, and the detection optical fiber (5), spectral components (7) and the data processor (8) that are connected successively with probe component (4);
Luminous organ (11) and the luminous power (12) of described light source part (1) for being electrically connected to, the luminous wave band of described luminous organ (11) is 300～400nm and 420～780nm;
Described light-operated parts (2) comprise focusing bonder (21) and the light splitting piece (22) be positioned on light source part (1) light path, the transmission end of described light splitting piece (22) is connected with luminous source optical fiber (3), be equipped with optical-electrical converter (23) on reflected light path, the outfan of optical-electrical converter (23) is connected with light source controller (24), and the outfan of described light source controller (24) is electrically connected to the input of light source part (1);
Described luminous source optical fiber (3) is the first luminous source optical fiber (31) and the secondary light source optical fiber (32) that are connected in parallel, is the light source of 300～400nm and 420～780nm for transmission wavelength respectively;
The first luminous source optical fiber end face (41) that with first luminous source optical fiber (31) be communicated with, the secondary light source fiber end face (42) that with secondary light source optical fiber (32) be communicated with, the detection optical fiber end face (43) that with detection optical fiber (5) be communicated with, color sensor (44), temperature sensor (45), humidity sensor (46) and the pressure transducer (47) of described probe component (4) for being equipped with on same plane; Symmetrical the first luminous source optical fiber end face (41) of the periphery of detection optical fiber end face (43) and secondary light source fiber end face (42), the mutual back gauge of the first luminous source optical fiber end face (41) and secondary light source fiber end face (42) and detection optical fiber end face (43) is 0.1～3mm; Described color sensor (44) is electrically connected to data processor (8) through the first preamplifier (441) and the first analog-digital converter (442); Described temperature sensor (45) is electrically connected to data processor (8) through the second preamplifier (451) and the second analog-digital converter (452); Described humidity sensor (46) is electrically connected to data processor (8) through the 3rd preamplifier (461) and the 3rd analog-digital converter (462); Described pressure transducer (47) is electrically connected to data processor (8) through the 4th preamplifier (471) and the 4th analog-digital converter (472);
On detection optical fiber (5) between described detection optical fiber end face (43) and spectral components (7), be equipped with filter part (6), described filter part (6) is for being the transmitance >=80% of 420～780nm at wavelength, and is that 300～400nm has mild rising edge and high permeability≤10%, the optical filter of transmitance≤1% at wavelength during lower than 300nm at wavelength;
The optical signal input of described spectral components (7) and the back segment of detection optical fiber are coupled by optical filter (6); The light intensity degree of each wavelength of input light is measured and quantized to spectral components (7), and measurement result outputs in data processor (8);
After data processor (8) receives and measures spectral signal by spectral components (7), calculate PRELIMINARY RESULTS, the data that obtain according to color sensor (44), temperature sensor (45), humidity sensor (46) and pressure transducer (47) respectively again, in conjunction with the height of the measurand of inputting, the data of body weight, measurement result is screened, according to age, the sex information of measurand, determine judgment threshold, obtain final diabetes testing result.
2. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 1, it is characterized in that: described light source part (1) is with the temperature sensor (13) be connected with luminous organ (11), and the outfan of temperature sensor (13) is electrically connected to the input of light-source temperature controller (14).
3. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 1 and 2, is characterized in that luminous organ (11) is one or more the combination in light emitting diode, electric filament lamp, Halogen light, neon lamp.
4. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 1 is characterized in that: described probe component (4) is with the aligner (48) of outstanding detection optical fiber end face (43) 1～5mm.
5. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 4 is characterized in that: described aligner (48) is 95～100% reflector plate for the reflectance that is 300～780nm to wavelength.
6. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 1 is characterized in that: described spectral components (7) is fiber spectrometer.
7. the noninvasive detection device of the diabetes based on the Advanced glycation end products fluorescence spectrum according to claim 1, it is characterized in that: described data processor (8) is microcomputer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013202551847U CN203303031U (en) | 2013-05-10 | 2013-05-10 | Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013202551847U CN203303031U (en) | 2013-05-10 | 2013-05-10 | Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203303031U true CN203303031U (en) | 2013-11-27 |
Family
ID=49609273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013202551847U Withdrawn - After Issue CN203303031U (en) | 2013-05-10 | 2013-05-10 | Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203303031U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103245650A (en) * | 2013-05-10 | 2013-08-14 | 铜陵易康达光电科技有限公司 | Noninvasive diabetes detection device based on advanced glycation end product fluorescence spectrum |
| CN104545812A (en) * | 2014-12-30 | 2015-04-29 | 中国科学院长春光学精密机械与物理研究所 | Detection depth adjustable non-invasive detection device for human body biochemical criteria |
| CN107242855A (en) * | 2017-06-05 | 2017-10-13 | 天津大学 | A kind of biological tissue's dynamic modulation spectral measurement device and method |
| CN110913753A (en) * | 2016-11-17 | 2020-03-24 | 生物智能股份有限公司 | Wearable electronic device for detecting medication compliance and/or counterfeit drugs |
-
2013
- 2013-05-10 CN CN2013202551847U patent/CN203303031U/en not_active Withdrawn - After Issue
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103245650A (en) * | 2013-05-10 | 2013-08-14 | 铜陵易康达光电科技有限公司 | Noninvasive diabetes detection device based on advanced glycation end product fluorescence spectrum |
| CN103245650B (en) * | 2013-05-10 | 2015-01-28 | 铜陵易康达光电科技有限公司 | Noninvasive diabetes detection device based on advanced glycation end product fluorescence spectrum |
| CN104545812A (en) * | 2014-12-30 | 2015-04-29 | 中国科学院长春光学精密机械与物理研究所 | Detection depth adjustable non-invasive detection device for human body biochemical criteria |
| CN110913753A (en) * | 2016-11-17 | 2020-03-24 | 生物智能股份有限公司 | Wearable electronic device for detecting medication compliance and/or counterfeit drugs |
| CN107242855A (en) * | 2017-06-05 | 2017-10-13 | 天津大学 | A kind of biological tissue's dynamic modulation spectral measurement device and method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210364421A1 (en) | Method and apparatus for determining markers of health by analysis of blood | |
| US11428574B2 (en) | Method and apparatus for determining markers of health by analysis of blood | |
| EP0548418B1 (en) | Non-invasive determination of glucose concentration in body of patient | |
| US5379764A (en) | Non-invasive determination of analyte concentration in body of mammals | |
| Boo et al. | Prediction of severe hyperbilirubinaemia using the Bilicheck transcutaneous bilirubinometer | |
| CN101716069A (en) | Human body oxidative stress non-invasive fluorescence detection device and method | |
| JPH0250733B2 (en) | ||
| US20110028808A1 (en) | Method and apparatus for examination of cancer, systemic lupus erythematosus (sle), or antiphospholipid antibody syndrome using near-infrared light | |
| CN107334477A (en) | A kind of double spectrum noninvasive dynamics monitoring devices | |
| CN100998499A (en) | Determination of a measure of a glycation end-product or disease state using tissue fluorescence | |
| CN203303031U (en) | Diabetes non-invasive detecting device based on glycation end product fluorescence spectrum | |
| Polley et al. | Development and optimization of a noncontact optical device for online monitoring of jaundice in human subjects | |
| CN103245650B (en) | Noninvasive diabetes detection device based on advanced glycation end product fluorescence spectrum | |
| CN101696931B (en) | Method and device for nondestructively testing material concentration | |
| CN104390918A (en) | Noninvasive detection system and method of diabetes and complications of diabetes | |
| CN108634964A (en) | A kind of non-invasive blood sugar instrument based on spectrum | |
| CN210300954U (en) | Noninvasive human body metabolic health index detection equipment | |
| CN110384507A (en) | A kind of detection method based on lip optics woundless measurement of blood sugar concentration | |
| KR20090036996A (en) | Non-prick based glucose sensor combining transmittance and reflectance using single wavelength with diverse light sources | |
| JPH09113439A (en) | Method and apparatus for measuring organic component | |
| EP4137063A1 (en) | Hemoglobin concentration measuring system, transvaginal probe, attachment, and hemoglobin concentration measuring method | |
| CN104181312B (en) | A kind of skin free cholesterol noninvasive detection device for atherosclerosis risk assessment | |
| RU2008126406A (en) | METHOD FOR OPTICAL DIAGNOSTICS OF LIVING MICRO-OBJECTS AND THEIR NANOCOMPONENTS AND DEVICE FOR ITS IMPLEMENTATION | |
| US20230148312A1 (en) | Device for non-invasive blood glucose concentration measurement | |
| CN105232055A (en) | Noninvasive glucometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20131127 Effective date of abandoning: 20150128 |
|
| RGAV | Abandon patent right to avoid regrant |